SCHEMBL4914853

SCHEMBL4914853

Cc1cc(C)n(-c2nc(Nc3cccc(Cl)c3)c3ccccc3n2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.57
ABCG2 Q9UNQ0 1/20 0.57
KDM4E B2RXH2 3/20 0.53
POLB P06746 2/20 0.52
USP2 O75604 1/20 0.52
ALOX15 P16050 1/20 0.52
PTPN7 P35236 1/20 0.52
CREBBP Q92793 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
EGFR P00533 2/20 0.51
FADS1 O60427 1/20 0.51
LCK P06239 1/20 0.50
THRB P10828 1/20 0.48
BCL6 P41182 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
LMNA P02545 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4908142 0.89 TDP1 (0.64) KDM4EPOLBUSP2ALOX15PTPN7
SCHEMBL4913824 0.88 BCL6 (0.62) PDE5AABCG2KDM4EPOLBUSP2
SCHEMBL4911556 0.88 POLB (0.61) ABCG2KDM4EPOLBUSP2ALOX15
SCHEMBL4904189 0.86 NPY5R (0.57) ABCG2KDM4EPOLBUSP2ALOX15
SCHEMBL4914616 0.84 MAPT (0.68) PDE5AABCG2KDM4EPOLBTDP1
SCHEMBL4910531 0.84 TDP1 (0.51) KDM4EPOLBUSP2ALOX15PTPN7
SCHEMBL4914836 0.84 TP53 (0.69) ABCG2POLBUSP2ALOX15PTPN7
SCHEMBL4907560 0.83 KDM4E (0.64) ABCG2KDM4EPOLBUSP2ALOX15
SCHEMBL4914786 0.82 TDP1 (0.55) ABCG2KDM4EPOLBUSP2ALOX15
SCHEMBL4908031 0.81 HTR2A (0.57) ABCG2KDM4EPOLBUSP2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861388-B1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE SANIONA AS (DK) 2017-07-05 EP claimed
US-8252806-B2 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-propylamine; 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-(4-morpholin-4-yl-phenyl)-amine; respiratory diseases, epilepsy, convulsions, seizures, gastrointestinal dysfunction, ischaemia, psychosis, schizophrenia, anxiety, depression, Alzheimer's disease NEUROSEARCH A/S (DK) 2012-08-28 US claimed
US-20080275045-A1 Potassium Channel Modulating Agents and Their Medical Use NEUROSEARCH A/S (DK) 2008-11-06 US claimed
CN-101115736-A Potassium channel modulating agents and their medical use NEUROSEARCH AS (DK) 2008-01-30 CN claimed
EP-1861388-A1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2007-12-05 EP claimed
WO-2006097441-A1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-09-21 WO claimed
EP-1861388-B1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE SANIONA AS (DK) 2017-07-05 EP disclosed
US-8252806-B2 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-propylamine; 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-(4-morpholin-4-yl-phenyl)-amine; respiratory diseases, epilepsy, convulsions, seizures, gastrointestinal dysfunction, ischaemia, psychosis, schizophrenia, anxiety, depression, Alzheimer's disease NEUROSEARCH A/S (DK) 2012-08-28 US disclosed
US-20080275045-A1 Potassium Channel Modulating Agents and Their Medical Use NEUROSEARCH A/S (DK) 2008-11-06 US disclosed
CN-101115736-A Potassium channel modulating agents and their medical use NEUROSEARCH AS (DK) 2008-01-30 CN disclosed
EP-1861388-A1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NeuroSearch A/S (DK) 2007-12-05 EP disclosed
WO-2006097441-A1 POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275045-A1 Potassium Channel Modulating Agents and Their Medical Use KCND2, KCNN3, KCNJ2 PDE5A 904/4885ABCG2 3090/4885KDM4E 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.